| Identification | Back Directory | [Name]
BMS-986165 | [CAS]
1609392-27-9 | [Synonyms]
Tyk2-IN-4
BMS-986165
Deucravacitinib
Deucravacitinib(BMS986165)
Deucravacitinib (TYK2-IN-4
TYK2-IN-4;BMS986165;BMS-986165;BMS 986165
6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide
6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide | [Molecular Formula]
C20H22N8O3 | [MOL File]
1609392-27-9.mol | [Molecular Weight]
422.45 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml | [form ]
A crystalline solid |
| Questions And Answer | Back Directory | [Uses]
BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis. |
|
|